Company intelligence / Profile preview

Micar Innovation

Ownership: Private
Development stage: Preclinical

Overview

Micar Innovation has developed a portfolio of at least ten new small molecule drug candidates at various stages of preclinical development. Lead programs are advancing toward preclinical trials with demonstrated non-clinical proof-of-concept in areas such as chronic pain, pancreatic cancer, melasma. The company also launched an initiative to study over one hundred new molecules targeting rare/ultra‐rare diseases.

Therapeutic areas: PulmonologyCardiovascularDermatologyOncologyRare DiseasesNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

15 assets

MIC-4578

Preclinical

14 more assets in the full pipeline.

Request access →

Partnerships

Major biopharmaceutical companies via Build-to-Buy partnershipsPioneering academic researchers/universities in EU & USA provide research collaboration/funding paths.

Beyond the preview

Go deeper on Micar Innovation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micar Innovation.

Explore the full profile